对间变性淋巴瘤激酶基因融合变异的非小细胞肺癌患者的治疗策略(6)
[28] Marsilje TH， Pei W， Chen B， et al. Synthesis， structureactivity relationships， and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2 ......
您现在查看是摘要页，全文长 1545 字符。